论文部分内容阅读
阿糖胞苷(Ara-C)以及正定霉素是急性骨髓性白血病化疗中不可缺少的药物。在以缓解为目的使用本药时,一般都与正定霉素等药物并用,以1日100mg/m~2的量经静脉给药。但最近通过改变给药量,为应用本药开辟了新的途径。其一是Ara-C的小剂量疗法。对急性自血病实施化疗的原理,是将白血病细胞“全部杀死”,即使杀不死,如能将其分化也好。因为白血病的实质是白细胞分化障碍,所以如有将其分化的方法,当然也可达到治愈的目的。事实上,在试管内已寻找到几种
Cytarabine (Ara-C) and norebinomycin are indispensable drugs for the chemotherapy of acute myeloid leukemia. In order to ease the use of the drug for the purpose, are generally used together with drugs such as adriamycin, in the 1st 100mg / m ~ 2 by intravenous administration. But recently by changing the dose, for the application of this drug has opened up new avenues. One is Ara-C’s low-dose therapy. The principle of chemotherapy for acute leukemias is to “kill all” leukemia cells, even if they do not kill them, if they can differentiate them. Because leukemia is the essence of leukocyte differentiation disorders, so if the method of differentiation, of course, can achieve the purpose of cure. In fact, several types have been found in test tubes